HIV-vaccine Research and Development in Thailand: Evolution and challenges

Punnee Pitisuttithum; Kachit Choopanya; Supachai Rerk-Ngnam

doi:10.1016/j.vaccine.2009.08.061

HIV-vaccine Research and Development in Thailand: Evolution and challenges

Punnee Pitisuttithum
, Kachit Choopanya
, Supachai Rerk-Ngnam

Department of Clinical Tropical Medicine

Taksin Hospital
Ministry of Public Health

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Thailand has been committed to HIV-Vaccine Research and Development since the launch of its National Plan, in 1993. Series of phase I/II trials, and two phase III clinical trials, have been conducted. The first efficacy trial was conducted with a high-risk group, injecting drug users (IDUs), and the second involved communities in the Eastern-seaboard provinces of Thailand. Both involved similar challenges in terms of infrastructure strengthening, capacity building, implementing the trials into the existing health system, staffing, and commitments. However, there were different issues in recruitment process, follow up, social impact events and community involvement since the target participants were different.

Original language	English
Pages (from-to)	B45-B49
Journal	Vaccine
Volume	28
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1016/j.vaccine.2009.08.061
Publication status	Published - 26 May 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 16 Peace, Justice and Strong Institutions

Keywords

Challenges
HIV-vaccine trials
Thailand

Access to Document

10.1016/j.vaccine.2009.08.061

Cite this

@article{aa3244cfecca479b991d68c5a2e1a335,

title = "HIV-vaccine Research and Development in Thailand: Evolution and challenges",

abstract = "Thailand has been committed to HIV-Vaccine Research and Development since the launch of its National Plan, in 1993. Series of phase I/II trials, and two phase III clinical trials, have been conducted. The first efficacy trial was conducted with a high-risk group, injecting drug users (IDUs), and the second involved communities in the Eastern-seaboard provinces of Thailand. Both involved similar challenges in terms of infrastructure strengthening, capacity building, implementing the trials into the existing health system, staffing, and commitments. However, there were different issues in recruitment process, follow up, social impact events and community involvement since the target participants were different.",

keywords = "Challenges, HIV-vaccine trials, Thailand",

author = "Punnee Pitisuttithum and Kachit Choopanya and Supachai Rerk-Ngnam",

year = "2010",

month = may,

day = "26",

doi = "10.1016/j.vaccine.2009.08.061",

language = "English",

volume = "28",

pages = "B45--B49",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "SUPPL. 2",

}

TY - JOUR

T1 - HIV-vaccine Research and Development in Thailand

T2 - Evolution and challenges

AU - Pitisuttithum, Punnee

AU - Choopanya, Kachit

AU - Rerk-Ngnam, Supachai

PY - 2010/5/26

Y1 - 2010/5/26

N2 - Thailand has been committed to HIV-Vaccine Research and Development since the launch of its National Plan, in 1993. Series of phase I/II trials, and two phase III clinical trials, have been conducted. The first efficacy trial was conducted with a high-risk group, injecting drug users (IDUs), and the second involved communities in the Eastern-seaboard provinces of Thailand. Both involved similar challenges in terms of infrastructure strengthening, capacity building, implementing the trials into the existing health system, staffing, and commitments. However, there were different issues in recruitment process, follow up, social impact events and community involvement since the target participants were different.

AB - Thailand has been committed to HIV-Vaccine Research and Development since the launch of its National Plan, in 1993. Series of phase I/II trials, and two phase III clinical trials, have been conducted. The first efficacy trial was conducted with a high-risk group, injecting drug users (IDUs), and the second involved communities in the Eastern-seaboard provinces of Thailand. Both involved similar challenges in terms of infrastructure strengthening, capacity building, implementing the trials into the existing health system, staffing, and commitments. However, there were different issues in recruitment process, follow up, social impact events and community involvement since the target participants were different.

KW - Challenges

KW - HIV-vaccine trials

KW - Thailand

UR - https://www.scopus.com/pages/publications/77952628320

U2 - 10.1016/j.vaccine.2009.08.061

DO - 10.1016/j.vaccine.2009.08.061

M3 - Article

C2 - 20510743

AN - SCOPUS:77952628320

SN - 0264-410X

VL - 28

SP - B45-B49

JO - Vaccine

JF - Vaccine

IS - SUPPL. 2

ER -

HIV-vaccine Research and Development in Thailand: Evolution and challenges

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this